O’Day touts cell therapies as Gilead beats on EPS

On his first earnings call as CEO of Gilead, Daniel O'Day said more M&A and deals by the bellwether within cell therapy are "fundamental and essential" as the company reported 1Q19 earnings Thursday that beat consensus on EPS but narrowly missed on revenues.

O'Day said Gilead Sciences Inc. (NASDAQ:GILD) has begun searching for a CEO to lead Kite Pharma Inc., which will become a separate business unit. Gilead had alluded to that plan when it first announced the acquisition...